Mazzella F and Bologna C
Ospedale Cotugno, Azienda dei Colli, Napoli, Italy Ospedale del Mare, ASL Na 1 centro, Napoli, Italy
Posters & Accepted Abstracts: Health Sci J
Background: The recent coronavirus pandemic (COVID-19) has gained attention especially for the severe acute respiratory syndrome (SARS-CoV-2) caused by the infection. While the incidence of gastrointestinal symptoms, such as diarrhea, was initially reported as negligible, not exceeding 1-3.8%, 1 a more recent study suggested that approximately 3.5% of patients report vomiting and even 10% nausea and diarrhea. In a Chinese study of 74 patients it was shown that up to 28% of cases presenting nausea, vomiting and diarrhea din’t present respiratory symptoms highlighting that the "gastrointestinal" presentation can also be the only manifestation of the disease. In patients who underwent endoscopy of the digestive tract, the virus was demonstrable on biopsies of the esophagus, stomach, duodenum and rectum, proving that the virus is present throughout the gastrointestinal tract.2 Several studies have reported that SARS-CoV-2 is isolable in faeces. In a series of 73 hospitalized subjects, the virus was present in the faeces from 1 to 12 days from the beginning of the infection in more than 50% of cases and> 20% of these patients had a positive search in the faeces even after the virus was no longer demonstrable in the respiratory tract . ACE2 is highly expressed in the small intestine, particularly at the enterocyte level. Discussion: more recently it has been reported that the penetration of SARS-CoV-2 into cells depends not only on ACE-2 but also on the transmembrane serine proteinase  which cleaves the protein S of human coronaviruses on the cell membrane, and that therefore they are both critical for viral kinetics. ACE2 and TMPRSS2 are co-expressed not only in alveolar cells but also in the glands of the upper esophagus, ileum and colon, suggesting that the virus can invade the digestive tract. Prevalence of infection and for stable preventive measures and more effective therapeutic strategies. References 1. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. 2. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, et al. (2020) Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69.